The evidence is compelling: vaccines may initiate autoimmunity, ushering in a range of diseases as a consequence. The inclusion of toxic metals like aluminum in vaccines raises questions about susceptibility and increased risk among specific groups.
Yehuda Shoenfeld is far from being dismissed as unscientific. With over three decades dedicated to immunology research and at the top of his field, Shoenfeld has authored foundational texts such as The Mosaic of Autoimmunity and Autoantibodies. His work is essential in clinical practice, and his nickname, the “Godfather of Autoimmunology,” reflects his deep impact on the study of the immune system attacking the body, manifesting in diseases like type 1 diabetes, ulcerative colitis, and multiple sclerosis.
However, recent shifts in immunology point to vaccines, particularly those containing aluminum, as a significant factor in the rising incidence of autoimmune diseases worldwide. This assertion is supported by a robust influx of research over the last 15 years, peaking in the last five. For instance, a recent study in Pharmacological Research by Shoenfeld and his team offers groundbreaking guidelines identifying four main risk groups for vaccine-induced autoimmunity.
The study highlights a paradox: vaccines prevent infections that can trigger autoimmunity, yet numerous reports link vaccines to autoimmune reactions. Diseases such as arthritis, lupus, diabetes, and others may develop post-vaccination, implicating various vaccines in triggering ASIA (Autoimmune/inflammatory Syndrome Induced by Adjuvants).
First introduced in the Journal of Autoimmunology four years ago, ASIA encompasses a set of symptoms including Chronic Fatigue Syndrome following exposure to adjuvants like aluminum. This burgeoning research area explores how environmental toxins prompt immune responses in predisposed individuals, potentially leading to autoimmune diseases.
Autoimmune diseases occur when the body’s defense system, designed to target foreign threats, mistakenly attacks the body itself. For example, if autoantibodies target joint tissue, rheumatoid arthritis can develop; if they attack pancreatic cells, Type 1 diabetes may result.
The paper emphasizes that the immune system must balance normal function with the risk of developing autoimmune diseases. Vaccination may disrupt this balance in vulnerable individuals, leading to autoimmune disorders and ASIA.
The research paper, “Predicting post-vaccination autoimmunity: Who might be at risk?” categorizes susceptible individuals as those with previous autoimmune responses to vaccines, a history of autoimmunity or allergic reactions, or those at high risk due to genetic predispositions or lifestyle factors like smoking or low vitamin D levels.
PREVIOUS ADVERSE REACTIONS
The document references five studies, including a case where a teenage girl died six months after receiving her third Gardasil injection against the HPV virus. Initially, she suffered symptoms like dizziness, numbness in her hands, and memory lapses. Post-second dose, she experienced worsening symptoms such as intermittent arm weakness, excessive fatigue necessitating daytime naps, intensified tingling, night sweats, chest pain, and palpitations. An exhaustive autopsy did not reveal the cause of death, but analysis of her blood and spleen tissue found HPV-16 L1 gene DNA fragments, identical to those in the Gardasil vaccine. These fragments, found bound to aluminum adjuvant, are believed to stimulate the immune system chronically for up to 8-10 years.
Shoenfeld and his team suggest that individuals who have previously experienced autoimmune or similar reactions to vaccinations should ideally avoid further immunizations with the same vaccine type.
ESTABLISHED AUTOIMMUNE CONDITIONS
The paper identifies those with established autoimmune conditions as another group that may be exempt from vaccinations. According to Shoenfeld and his colleagues, vaccines are less effective and may even trigger symptom flares in these patients. Vaccinations containing live viruses, such as the chickenpox, yellow fever, and MMR vaccines, are typically advised against due to the risk of uncontrolled viral replication. Conversely, inactivated vaccines, often containing aluminum, also pose a risk due to their association with autoimmunity.
Recent studies noted that patients with autoimmune rheumatic diseases who received the aluminum-free influenza vaccine reported increased joint pain and fever compared to non-autoimmune individuals. Moreover, these patients developed new autoantibody types post-vaccination, which persisted and could predict future autoimmune diseases even in symptom-free patients.
While some research suggests vaccines are generally safe for patients with established autoimmune diseases like rheumatoid arthritis and lupus, these studies do not account for severe or active cases, leading researchers to caution that the potential benefits of vaccination should be carefully weighed against the risks.
PATIENTS WITH A HISTORY OF ALLERGY
Typically, vaccine trials exclude vulnerable individuals, particularly those with allergies, which Shoenfeld and Soriano identify as a “selection bias.” This likely underestimates serious adverse reactions in the broader population, where vaccination is compulsory. Indeed, the actual rate of allergic reactions to vaccines, which may involve ingredients like gelatin or egg proteins, is thought to be significantly higher than the reported range of one in 50,000 to one million doses.
Vaccines contain multiple potential allergens, including those derived from hen’s egg, horse serum, baker’s yeast, various antibiotics, formaldehyde, lactose, and even unintentional ingredients like latex. It is crucial to evaluate individuals’ allergy histories before vaccination. However, some allergic reactions may not be apparent until after vaccination has been administered.
Healthcare professionals might reassure patients that persistent swelling at the injection site is normal, but immunologists have a different view. They explain that “aluminum sensitization” can cause nodules at the injection site that may take weeks or months to resolve and can persist for years. In such cases, a patch test may be necessary to confirm sensitivity and guide future vaccination decisions.
THE CHALLENGE WITH ALUMINUM
Aluminum has been used as a vaccine adjuvant since 1926, originally praised for enhancing antibody responses more effectively than antigens alone. For decades, the belief that aluminum merely created a “depot effect” prevailed, slowly releasing the antigen to boost the immune response. However, recent research challenges this notion, revealing that aluminum can provoke a robust immune response shortly after administration.
Recent studies at the University of British Columbia and the University of Colorado demonstrate that aluminum adjuvant in vaccines not only alters gene expression related to autoimmunity but also binds rapidly to injected host DNA, triggering a complex immune reaction that is not yet fully understood. This burgeoning field of research continues to explore the broad and intricate effects of aluminum on the immune system and its potential link to autoimmunity and other chronic conditions.
THE IMPLICATIONS OF MACROPHAGIC MYOFASCIITIS
The phenomenon known as “translocation” of aluminum within the body is arguably one of the most alarming findings in contemporary aluminum research. In 1998, French scientist Romain Gherardi and his team identified a new condition in post-vaccination patients showing symptoms akin to Chronic Fatigue Syndrome, including swollen lymph nodes, joint and muscle pain, and severe fatigue. Deltoid muscle biopsies from these patients showed unique lesions up to 1 cm in diameter. Astonishingly, these lesions predominantly contained macrophages, large immune cells that engulf pathogens, filled with clusters of aluminum nanocrystals.
To further understand this, Gherardi’s group injected mice with aluminum, discovering through their 2013 study that these particles were absorbed by macrophages and formed granulomas resembling MMF that migrated to distant organs like the lymph nodes, spleen, liver, and eventually the brain.
“This conclusively indicates that the long-term presence of adjuvant aluminum within phagocytic cells is a precursor to its slow journey to the brain and subsequent neurotoxic effects,” Gherardi noted in his 2015 review in Frontiers in Neurology.
A more distressing study by Spanish veterinary scientist Lluis Lujan looked at ovine ASIA following the mandatory vaccination of sheep in Spain in 2008 against bluetongue. His 2013 findings revealed immediate adverse reactions in only 0.5% of aluminum-vaccinated sheep, including lethargy, temporary blindness, stupor, and severe neurological symptoms akin to meningoencephalitis observed in humans. While many initially recovered, post-mortem analysis of those that did not survive showed acute brain inflammation.
The chronic phase affected a staggering 50-70% of the sheep, sometimes the entire flock, triggered by cold exposure. Symptoms progressed from restlessness and compulsive wool-biting to severe skin inflammation, generalized weakness, drastic weight loss, muscle tremors, and ultimately, a terminal phase where sheep collapsed, became comatose, and died. Examinations revealed severe neuron damage and aluminum accumulation in nerve tissues.
“The immune response to aluminum represents a significant health concern,” Gherardi emphasizes, calling for more rigorous examination of the safety concerns associated with the persistent nature and brain accumulation of aluminum particles.
Addressing the issue of individuals prone to developing autoimmunity, Soriano and Shoenfeld highlight a final category: those at risk of autoimmune disease, including those with a genetic predisposition or detectable autoantibodies, indicating potential disease long before symptoms manifest. They note that vaccinations might trigger or exacerbate such conditions.
Additionally, smokers are at a particularly high risk of developing autoimmune diseases. With roughly 18% of Americans smoking, this represents about 42 million people at increased risk, compounded by each vaccination.
Other factors linked to a heightened risk of autoimmunity include high estrogen levels and low vitamin D levels, suggesting that those on hormonal therapies or with low vitamin D should exercise caution regarding vaccinations.
While Shoenfeld does not advocate for blanket immunization exclusion, the paper concludes that, for most people, vaccines do not pose a risk of autoimmune disease and should be administered as recommended. Yet, this stands in sharp contrast to the rest of the document, which urges careful consideration of the “potential benefits of vaccination against its potential risks.”
This reflects a peculiar dichotomy seen in recent immunology research, attempting to reconcile longstanding beliefs in vaccine safety with a decade of disturbing new findings. The debate continues, with a 2013 review by Shoenfeld and other immunologists cataloging vaccine-related issues from Gardasil fatalities and narcolepsy outbreaks to infertility and chronic fatigue, highlighting the need for a deeper understanding of vaccine adjuvants and their role in triggering autoimmunity. This evolving discourse signals a critical shift towards reevaluating the safety and efficacy of vaccines and their components, forecasting a future where vaccine safety may achieve new levels of scrutiny and assurance.
Or consider this argument: “Despite substantial financial investments in vaccine research, the literature is scant on observational studies and almost devoid of randomized clinical trials that assess the impact on mortality of existing vaccines. A recent study indicated a higher hospitalization rate correlating with increased vaccine doses, revealing a mortality rate ratio of 1.5 when comparing children receiving 5-8 doses to those receiving 1-4 doses, which points to a statistically significant rise in deaths associated with higher doses of vaccines. Given the millions of infants vaccinated each year, it’s critical for health authorities to possess scientific data from studies examining the synergistic toxicity of all vaccine combinations…” This might sound like rhetoric from an anti-vaccine advocate, but it isn’t.
And then there’s this clincher: “The US Supreme Court has decreed that vaccine manufacturers are not liable for lawsuits claiming that a vaccine’s design is flawed. Therefore, there is a pressing need for innovative clinical trial designs, and the vaccines themselves require reevaluation.” Even leading immunologists globally recognize the urgency of revisiting vaccine design.
Autoimmune diseases are now the third leading cause of illness and death globally, and they rank among the top ten killers of young women in America. The American Autoimmune Related Diseases Association estimates that 50 million Americans live with one of 88 identified autoimmune diseases, ranging from type 1 diabetes to systemic lupus erythematosus, with global estimates suggesting that one in five people are affected. An additional 40 conditions are believed to be related to immune system dysfunction. These diseases are typically severe—often disabling, costly to manage, and without a cure—and their prevalence is growing at an alarming rate.
As more research accumulates, it becomes increasingly challenging for pro-vaccine immunologists to dismiss concerns or avoid psychological strain—possibly bordering on dissociative identity disorder or outright mental collapse. A decade of advanced research into the effects of aluminum on the immune system has primarily demonstrated their misconceptions and significant gaps in knowledge. After 90 years, the medical community has started to seriously investigate the implications of injecting metallic toxins into infants. What more remains uncovered? ASIA’s ramifications are profound. (It’s unfortunate for those who endured chronic fatigue under misconceived psychological explanations.) What if the problems extend beyond the visible minority affected, like Lujan’s sheep? Could seemingly unaffected individuals have aluminum nanocrystals silently accumulating in their brains? Could ASIA encompass conditions like Alzheimer’s, ALS, autism, and ADD—just to name a few beginning with ‘A’?
Even if immunologists continue to view the situation through rose-tinted glasses, and vaccine components contribute only marginally to the surge in autoimmunity, the troubling aspects of vaccines will become increasingly difficult to overlook. As global vaccination rates climb, the implications of a 20-year lag in addressing these concerns are dire for those affected. Amid the furor surrounding events like the Disneyland measles outbreak and the strong push by vaccine advocates, time is running short for medical professionals and researchers who acknowledge the detrimental aspects of vaccines and their additives to enact change. With little financial incentive for vaccine redesign and looming universal vaccine mandates, the outlook for addressing these concerns remains bleak, regardless of previous severe allergic reactions.